

CONMED CORP
Form 10-Q
May 04, 2009

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE
SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended
March 31, 2009

Commission File Number 0-16093

CONMED CORPORATION
(Exact name of registrant as specified in its charter)

New York
(State or other jurisdiction of
incorporation or organization)

16-0977505
(I.R.S. Employer
Identification No.)

525 French Road, Utica, New York
(Address of principal executive offices)

13502
(Zip Code)

(315) 797-8375
(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for shorter period that the registrant was required to submit and post such files). Yes No

Edgar Filing: CONMED CORP - Form 10-Q

Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See definition of “accelerated filer”, “large accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act (Check one).

Large accelerated filer Accelerated filer Non-accelerated filer Smaller reporting company

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes No

The number of shares outstanding of registrant's common stock, as of April 27, 2009 is 29,040,283 shares.

CONMED CORPORATION

QUARTERLY REPORT ON FORM 10-Q
FOR THE QUARTER ENDED MARCH 31, 2009

PART I FINANCIAL INFORMATION

Item Number		Page
<u>Item 1.</u>	<u>Financial Statements</u>	
-	<u>Consolidated Condensed Statements of Income for the three months ended March 31, 2008 and 2009</u>	1
-	<u>Consolidated Condensed Balance Sheets as of December 31, 2008 and March 31, 2009</u>	2
-	<u>Consolidated Condensed Statements of Cash Flows for the three months ended March 31, 2008 and 2009</u>	3
-	<u>Notes to Consolidated Condensed Financial Statements</u>	4
<u>Item 2.</u>	<u>Management's Discussion and Analysis of Financial Condition and Results of Operations</u>	16
<u>Item 3.</u>	<u>Quantitative and Qualitative Disclosures About Market Risk</u>	32
<u>Item 4.</u>	<u>Controls and Procedures</u>	32
<u>PART II OTHER INFORMATION</u>		
<u>Item 1.</u>	<u>Legal Proceedings</u>	32
<u>Item 6.</u>	<u>Exhibits</u>	33
<u>Signatures</u>		34

Table of Contents

PART I FINANCIAL INFORMATION

Item 1.

CONMED CORPORATION
CONSOLIDATED CONDENSED STATEMENTS OF INCOME
(Unaudited, in thousands except per share amounts)

	Three Months Ended March 31,	
	As Adjusted (Note 15) 2008	2009
Net sales	\$ 190,773	\$ 164,062
Cost of sales	93,009	87,710
Gross profit	97,764	76,352
Selling and administrative expense	68,646	61,853
Research and development expense	8,078	8,489
Other expense (income)	-	(1,336)
	76,724	69,006
Income from operations	21,040	7,346
Gain on early extinguishment of debt	-	1,083
Amortization of debt discount	1,202	1,045
Interest expense	3,174	1,488
Income before income taxes	16,664	5,896
Provision for income taxes	6,412	1,411
Net income	\$ 10,252	\$ 4,485
Per share data:		
Net income		
Basic	\$.36	\$.15
Diluted	.35	.15

Weighted average common shares

Basic	28,625	29,030
Diluted	29,006	29,061

See notes to consolidated condensed financial statements.

Table of Contents

CONMED CORPORATION
 CONSOLIDATED CONDENSED BALANCE SHEETS
 (Unaudited, in thousands except share and per share amounts)

	As Adjusted (Note 15) December 31, 2008	March 31, 2009
ASSETS		
Current assets:		
Cash and cash equivalents	\$ 11,811	\$ 12,178
Accounts receivable, net	96,515	90,529
Inventories	159,976	159,837
Income taxes receivable	-	501
Deferred income taxes	14,742	14,375
Prepaid expenses and other current assets	11,218	11,120
Total current assets	294,262	288,540
Property, plant and equipment, net	143,737	147,297
Goodwill	290,245	290,473
Other intangible assets, net	195,939	194,575
Other assets	7,478	6,925
Total assets	\$ 931,661	\$ 927,810
LIABILITIES AND SHAREHOLDERS' EQUITY		
Current liabilities:		
Current portion of long-term debt	\$ 3,185	\$ 3,185
Accounts payable	35,887	28,457
Accrued compensation and benefits	20,129	19,964
Income taxes payable	1,279	-
Other current liabilities	14,434	13,437
Total current liabilities	74,914	65,043
Long-term debt	182,739	186,787
Deferred income taxes	88,468	97,871
Other long-term liabilities	45,325	23,479
Total liabilities	391,446	373,180
Commitments and contingencies		
Shareholders' equity:		
Preferred stock, par value \$.01 per share; authorized 500,000 shares; none outstanding	-	-
Common stock, par value \$.01 per share; 100,000,000 shares authorized; 31,299,203 shares issued in 2008 and 2009, respectively	313	313
Paid-in capital	313,830	314,679

Edgar Filing: CONMED CORP - Form 10-Q

Retained earnings	314,373	318,825
Accumulated other comprehensive loss	(31,032)	(22,079)
Less: 2,274,822 and 2,268,158 shares of common stock in treasury, at cost in 2008 and 2009, respectively	(57,269)	(57,108)
Total shareholders' equity	540,215	554,630
Total liabilities and shareholders' equity	\$ 931,661	\$ 927,810

See notes to consolidated condensed financial statements.

Table of Contents

CONMED CORPORATION
 CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS
 (Unaudited, in thousands)

	Three Months Ended March 31,	
	As Adjusted (Note 15)	
	2008	2009
Cash flows from operating activities:		
Net income	\$ 10,252	\$ 4,485
Adjustments to reconcile net income to net cash provided by operating activities:		
Depreciation	3,305	4,011
Amortization of debt discount	1,202	1,045
Amortization, all other	4,524	4,395
Stock-based compensation	942	974
Deferred income taxes	5,335	2,535
Gain on early extinguishment of debt	-	(1,083)
Pension gain, net	-	(1,882)
Sale of accounts receivable to (collections for) purchaser	3,000	(2,000)
Increase (decrease) in cash flows from changes in assets and liabilities:		
Accounts receivable	(3,482)	5,472
Inventories	1,326	(3,391)
Accounts payable	164	(4,643)
Income taxes receivable (payable)	1,841	(2,141)
Accrued compensation and benefits	(1,573)	41
Other assets	(1,719)	(133)
Other liabilities	(4,363)	(969)
Net cash provided by operating activities	20,754	6,716
Cash flows from investing activities:		
Payments related to business acquisitions	(14,758)	(112)
Purchases of property, plant and equipment	(5,975)	(7,441)
Net cash used in investing activities	(20,733)	(7,553)
Cash flows from financing activities:		
Net proceeds from common stock issued under employee plans	221	110
Proceeds of senior credit agreement	-	12,000
Payments on long term debt	(125)	(7,913)

Edgar Filing: CONMED CORP - Form 10-Q

Net change in cash overdrafts	-	(3,164)
Net cash provided by financing activities	96	1,033
Effect of exchange rate changes on cash and cash equivalents	1,596	171
Net increase in cash and cash equivalents	1,713	367
Cash and cash equivalents at beginning of period	11,695	11,811
Cash and cash equivalents at end of period	\$ 13,408	\$ 12,178

See notes to consolidated condensed financial statements.

Table of Contents

CONMED CORPORATION
 NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS
 (Unaudited, in thousands except share and per share amounts)

Note 1 – Operations and significant accounting policies

Organization and operations

CONMED Corporation (“CONMED”, the “Company”, “we” or “us”) is a medical technology company with an emphasis on surgical devices and equipment for minimally invasive procedures and monitoring. The Company’s products serve the clinical areas of arthroscopy, powered surgical instruments, electrosurgery, cardiac monitoring disposables, endosurgery and endoscopic technologies. They are used by surgeons and physicians in a variety of specialties including orthopedics, general surgery, gynecology, neurosurgery, and gastroenterology.

Note 2 - Interim financial information

The accompanying unaudited consolidated condensed financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for annual financial statements. Results for the period ended March 31, 2009 are not necessarily indicative of the results that may be expected for the year ending December 31, 2009.

The consolidated condensed financial statements and notes thereto should be read in conjunction with the financial statements and notes for the year-ended December 31, 2008 included in our Annual Report on Form 10-K. Effective January 1, 2009, we adopted FSP APB 14-1 which requires retroactive presentation. See Note 15 for disclosure of the effect on prior period results.

Note 3 – Other comprehensive income

Comprehensive income consists of the following:

	Three months ended March 31,	
	2008	2009
Net income	\$ 10,252	\$ 4,485
Other comprehensive income:		
Pension liability	90	12,349
Foreign currency translation adjustment	1,985	(3,396)
Comprehensive income	\$ 12,327	\$ 13,438

Table of Contents

Accumulated other comprehensive income (loss) consists of the following:

	Pension Liability	Cumulative Translation Adjustments	Accumulated Other Comprehensive Income (loss)
Balance, December 31, 2008	\$ (27,592)	\$ (3,440)	\$ (31,032)
Pension liability	12,349	-	12,349
Foreign currency translation adjustments	-	(3,396)	(3,396)
Balance, March 31, 2009	\$ (15,243)	\$ (6,836)	\$ (22,079)

Note 4 – Fair value of financial instruments

The carrying amounts reported in our balance sheets for cash and cash equivalents, accounts receivable, accounts payable and long-term debt excluding the 2.50% convertible senior subordinated notes (the “Notes”) approximate fair value. The fair value of the Notes approximated \$97.2 million and \$90.9 million at December 31, 2008 and March 31, 2009, respectively, based on their quoted market price. We repurchased and retired \$9.9 million of the Notes during the three months ended March 31, 2009 for \$7.8 million and recorded a net gain of \$1.1 million on the early extinguishment of debt as further described in Note 15.

Note 5 - Inventories

Inventories consist of the following:

	December 31, 2008	March 31, 2009
Raw materials	\$ 55,022	\$ 51,410
Work-in-process	22,177	22,830
Finished goods	82,777	85,597
Total	\$ 159,976	\$ 159,837

Note 6 – Earnings per share

Basic earnings per share (“basic EPS”) is computed by dividing net income by the weighted average number of common shares outstanding for the reporting period. Diluted earnings per share (“diluted EPS”) gives effect to all dilutive potential shares outstanding resulting from employee stock options, restricted stock units and stock appreciation rights during the period. The following table sets forth the computation of basic and diluted earnings per share for the three month periods ended March 31, 2008 and 2009.

Table of Contents

	Three months ended March 31,	
	2008	2009
Net income	\$ 10,252	\$ 4,485
Basic – weighted average shares outstanding	28,625	29,030
Effect of dilutive potential securities	381	31
Diluted – weighted average shares outstanding	29,006	29,061
Basic EPS	\$.36	\$.15
Diluted EPS	.35	.15

The shares used in the calculation of diluted EPS exclude options and SARs to purchase shares where the exercise price was greater than the average market price of common shares for the period. Such shares aggregated approximately 1.0 million and 2.5 million for the three months ended March 31, 2008 and 2009, respectively. Upon conversion of the Notes, the holder of each Note will receive the conversion value of the Note payable in cash up to the principal amount of the Note and CONMED common stock for the Note's conversion value in excess of such principal amount. As of March 31, 2009, our share price has not exceeded the conversion price of the Notes, therefore the conversion value was less than the principal amount of the Notes. Under the net share settlement method and in accordance with Emerging Issues Task Force (“EITF”) Issue 04-8, “The Effect of Contingently Convertible Debt on Diluted Earnings per Share”, there were no potential shares issuable under the Notes to be used in the calculation of diluted EPS. The maximum number of shares we may issue with respect to the Notes is 5,750,000.

Note 7 – Goodwill and other intangible assets

The changes in the net carrying amount of goodwill for the three months ended March 31, 2009 are as follows:

Balance as of January 1, 2009	\$ 290,245
Adjustments to goodwill resulting from	
business acquisitions finalized	76
Foreign currency translation	152
Balance as of March 31, 2009	\$ 290,473

Goodwill associated with each of our principal operating units is as follows:

	December 31, 2008	March 31, 2009
CONMED Electrosurgery	\$ 16,645	\$ 16,645

Edgar Filing: CONMED CORP - Form 10-Q

CONMED Endosurgery	42,439	42,439
CONMED Linvatec	171,437	171,589
CONMED Patient Care	59,724	59,800
Balance	\$ 290,245	\$ 290,473

6

Table of Contents

Other intangible assets consist of the following:

	December 31, 2008		March 31, 2009	
	Gross Carrying Amount	Accumulated Amortization	Gross Carrying Amount	Accumulated Amortization
Amortized intangible assets:				
Customer relationships	\$ 127,594	\$ (32,187)	\$ 127,594	\$ (33,260)
Patents and other intangible assets	40,714	(28,526)	40,903	(29,006)
Unamortized intangible assets:				
Trademarks and tradenames	88,344	-	88,344	-
	\$ 256,652	\$ (60,713)	\$ 256,841	\$ (62,266)

Other intangible assets primarily represent allocations of purchase price to identifiable intangible assets of acquired businesses. The weighted average amortization period for intangible assets which are amortized is 24 years. Customer relationships are being amortized over a weighted average life of 32 years. Patents and other intangible assets are being amortized over a weighted average life of 13 years.

Amortization expense related to intangible assets which are subject to amortization totaled \$1,548 and \$1,553 in the three months ended March 31, 2008 and 2009, respectively. These amounts have been included in selling and administrative expense on the Consolidated Condensed Statements of Income.

The estimated amortization expense for the year ending December 31, 2009, including the quarterly period ended March 31, 2009, and for each of the five succeeding years, is as follows:

2009	6,155
2010	6,066
2011	5,878
2012	5,818
2013	5,340
2014	4,934

Note 8 — Guarantees

We provide warranties on certain of our products at the time of sale. The standard warranty period for our capital and reusable equipment is generally one year. Liability under service and warranty policies is based upon a review of historical warranty and service claim experience. Adjustments are made to accruals as claim data and historical experience warrant.

Changes in the carrying amount of service and product warranties for the three months ended March 31, 2009 are as follows:

Balance as of January 1, 2009	\$ 3,341
-------------------------------	----------

Provision for warranties	850
Claims made	(888)
Balance as of March 31, 2009	\$ 3,303

7

Table of Contents

Note 9 – Pension plan

Net periodic pension costs consist of the following:

	Three months ended March 31,	
	2008	2009
Service cost	\$ 1,536	\$ 1,747
Interest cost on projected benefit obligation	843	1,139
Expected return on plan assets	(845)	(999)
Net amortization and deferral	142	599
Curtailment gain	-	(4,368)
Net periodic pension cost (gain)	\$ 1,676	\$ (1,882)

During the first quarter of 2009, the Company announced the freezing of benefit accruals under the defined benefit pension plan for United States employees (“the Plan”) effective May 14, 2009. As a result, the Company recorded a curtailment gain of \$4.4 million and a reduction in accrued pension of \$11.4 million which is included in other long term liabilities.

We are required and expect to make \$6.1 million in contributions to our pension plan in 2009. We did not make any contributions in the quarter ended March 31, 2009.

Note 10 — Other expense (income)

Other expense (income) consists of the following:

	Three months ended March 31,	
	2008	2009
New plant/facility consolidation costs	\$ -	\$ 546
Net pension gain	-	(1,882)
Other income	\$ -	\$ (1,336)

During the first quarter of 2009 we incurred \$3.5 million in restructuring costs of which \$0.5 million have been recorded in other expense and include charges related to the consolidation of our distribution centers. The remaining \$3.0 million in restructuring costs have been charged to cost of goods sold and represent startup activities associated with a new manufacturing facility in Chihuahua, Mexico and the closure of two Utica, New York area manufacturing

facilities (see Note 14).

During the first quarter of 2009, we elected to freeze benefit accruals under the defined benefit pension plan for United States employees, effective May 14, 2009. As a result, we recorded a net pension gain of \$1.9 million associated with the elimination of future benefit accruals under the pension plan (see Note 9).

Table of Contents

Note 11 — Business Segments and Geographic Areas

CONMED conducts its business through five principal operating segments, CONMED Endoscopic Technologies, CONMED Endosurgery, CONMED Electrosurgery, CONMED Linvatec and CONMED Patient Care. We believe each of our segments are similar in the nature of their products, production processes, customer base, distribution methods and regulatory environment. In accordance with Statement of Financial Accounting Standards No. 131 “Disclosures About Segments of an Enterprise and Related Information” (“SFAS 131”), our CONMED Endosurgery, CONMED Electrosurgery and CONMED Linvatec operating segments also have similar economic characteristics and therefore qualify for aggregation under SFAS 131. Our CONMED Patient Care and CONMED Endoscopic Technologies operating units do not qualify for aggregation under SFAS 131 since their economic characteristics do not meet the criteria for aggregation as a result of the lower overall operating income (loss) in these segments.

CONMED Endosurgery, CONMED Electrosurgery and CONMED Linvatec consist of a single aggregated segment comprising a complete line of endo-mechanical instrumentation for minimally invasive laparoscopic procedures, electrosurgical generators and related surgical instruments, arthroscopic instrumentation for use in orthopedic surgery and small bone, large bone and specialty powered surgical instruments. CONMED Patient Care product offerings include a line of vital signs and cardiac monitoring products as well as suction instruments & tubing for use in the operating room. CONMED Endoscopic Technologies product offerings include a comprehensive line of minimally invasive endoscopic diagnostic and therapeutic instruments used in procedures which require examination of the digestive tract.

The following is net sales information by product line and reportable segment:

	Three months ended March 31,	
	2008	2009
Arthroscopy	\$ 75,807	\$ 63,832
Powered Surgical Instruments	40,173	32,823
CONMED Linvatec	115,980	96,655
CONMED Electrosurgery	26,784	22,380
CONMED Endosurgery	15,201	14,526
CONMED Endosurgery, Electrosurgery and Linvatec	157,965	133,561
CONMED Patient Care	20,311	18,465
CONMED Endoscopic Technologies	12,497	12,036
Total	\$ 190,773	\$ 164,062

Total assets, capital expenditures, depreciation and amortization information are not available by segment.

The following is a reconciliation between segment operating income (loss) and income (loss) before income taxes:

Table of Contents

	Three months ended March 31,	
	2008	2009
CONMED Linvatec, Electrosurgery and Endosurgery	\$ 27,497	\$ 12,511
CONMED Patient Care	554	(440)
CONMED Endoscopic Technologies	(2,479)	(1,842)
Corporate	(4,532)	(2,883)
Income from operations	21,040	7,346
Gain on early extinguishment of debt	-	1,083
Notes discount amortization	1,202	1,045
Interest expense	3,174	1,488
Income before income taxes	\$ 16,664	\$ 5,896

Note 12 – Legal proceedings

From time to time, we are a defendant in certain lawsuits alleging product liability, patent infringement, or other claims incurred in the ordinary course of business. Likewise, from time to time, the Company may receive a subpoena from a government agency such as the Equal Employment Opportunity Commission, Occupational Safety and Health Administration, the Department of Labor, the Treasury Department, and other federal and state agencies or foreign governments or government agencies. These subpoenas may or may not be routine inquiries, or may begin as routine inquiries and over time develop into enforcement actions of various types. The product liability claims are generally covered by various insurance policies, subject to certain deductible amounts, maximum policy limits and certain exclusions in the respective policies or required as a matter of law. In some cases we may be entitled to indemnification by third parties. When there is no insurance coverage, as would typically be the case primarily in lawsuits alleging patent infringement or in connection with certain government investigations, or indemnification obligation of a third party we establish reserves sufficient to cover probable losses associated with such claims. We do not expect that the resolution of any pending claims or investigations will have a material adverse effect on our financial condition, results of operations or cash flows. There can be no assurance, however, that future claims or investigations, or the costs associated with responding to such claims or investigations, especially claims and investigations not covered by insurance, will not have a material adverse effect on our future performance.

Manufacturers of medical products may face exposure to significant product liability claims. To date, we have not experienced any product liability claims that are material to our financial statements or condition, but any such claims arising in the future could have a material adverse effect on our business or results of operations. We currently maintain commercial product liability insurance of \$25 million per incident and \$25 million in the aggregate annually, which we believe is adequate. This coverage is on a claims-made basis. There can be no assurance that claims will not exceed insurance coverage, that the carriers will be solvent or that such insurance will be available to us in the future at a reasonable cost.

Our operations are subject, and in the past have been subject, to a number of environmental laws and regulations governing, among other things, air emissions, wastewater discharges, the use, handling and disposal of hazardous substances and wastes, soil and groundwater remediation and employee health and safety. In some jurisdictions environmental requirements may be expected to become more stringent in the future. In the United States certain environmental laws can impose liability for the entire cost of site restoration upon each of the parties that may have contributed to conditions at the site regardless of fault or the lawfulness of the party's activities. While we do not

believe that the present costs of environmental compliance and remediation are material, there can be no assurance that future compliance or remedial obligations could not have a material adverse effect on our financial condition, results of operations or cash flows.

Table of Contents

On April 7, 2006, CONMED received a copy of a complaint filed in the United States District for the Northern District of New York on behalf of a purported class of former CONMED Linvatec sales representatives. The complaint alleges that the former sales representatives were entitled to, but did not receive, severance in 2003 when CONMED Linvatec restructured its distribution channels. The range of loss associated with this complaint ranges from \$0 to \$3.0 million, not including any interest, fees or costs that might be awarded if the five named plaintiffs were to prevail on their own behalf as well as on behalf of the approximately 70 (or 90 as alleged by the plaintiffs) other members of the purported class. CONMED Linvatec did not generally pay severance during the 2003 restructuring because the former sales representatives were offered sales positions with CONMED Linvatec's new manufacturer's representatives. Other than three of the five named plaintiffs in the class action, nearly all of CONMED Linvatec's former sales representatives accepted such positions.

The Company's motions to dismiss and for summary judgment, which were heard at a hearing held on January 5, 2007, were denied by a Memorandum Decision and Order dated May 22, 2007. The District Court also granted the plaintiffs' motion to certify a class of former CONMED Linvatec sales representatives whose employment with CONMED Linvatec was involuntarily terminated in 2003 and who did not receive severance benefits. With discovery essentially completed, on July 21, 2008, the Company filed motions seeking summary judgment and to decertify the class. In addition, on July 21, 2008, Plaintiffs filed a motion seeking summary judgment. These motions were submitted for decision on August 26, 2008. There is no fixed time frame within which the Court is required to rule on the motions. The Company believes there is no merit to the claims asserted in the Complaint, and plans to vigorously defend the case. There can be no assurance, however, that the Company will prevail in the litigation.

Note 13 – New accounting pronouncements

In March 2008, the FASB issued SFAS No. 161, "Disclosures About Derivative Instruments and Hedging Activities – an amendment of FASB Statement No. 133" ("SFAS 161"). SFAS 161 expands quarterly disclosure requirements about an entity's derivative instruments and hedging activities. SFAS 161 became effective for fiscal years and interim periods beginning after November 15, 2008. The SFAS was not material to our quarterly disclosures.

In December 2008, the Financial Accounting Standards Board issued FASB Staff Position (FSP) No. 132(R)-1, "Employers' Disclosures about Postretirement Benefit Plan Assets" to provide guidance on an employer's disclosures about plan assets of a defined benefit pension plan. FSP No. 132(R)-1 is effective for our year ending December 31, 2009.

In April 2009, the Financial Accounting Standards Board issued FASB Staff Position (FSP) No. 141(R)-1, "Accounting for Assets Acquired and Liabilities Assumed in a Business Combination That Arise from Contingencies" which amends FASB Statement No 141(R), "Business Combinations" allowing companies to continue to account for contingent assets and liabilities acquired in a business combination (acquired contingencies) based on the existing requirements of FASB Statement No. 141, "Business Combinations". Companies will be required to recognize acquired contingencies at their fair values only if that value can be reasonably estimated during the allocation period. Otherwise, companies would typically account for the acquired contingencies in accordance with FASB Statement No. 5, Accounting for Contingencies (FAS 5). This does not have a material impact on our consolidated financial statements.

Table of Contents

Note 14 – Restructuring

During the second quarter of 2008, we announced a plan to restructure certain of our operations. The restructuring plan includes the closure of two manufacturing facilities located in the Utica, New York area totaling approximately 200,000 square feet with manufacturing to be transferred into either our Corporate headquarters location in Utica, New York or into a newly constructed leased manufacturing facility in Chihuahua, Mexico. In addition, manufacturing presently done by a contract manufacturing facility in Juarez, Mexico is being transferred in-house to the Chihuahua facility. Finally, certain domestic distribution activities are being centralized in a new leased consolidated distribution center in Atlanta, Georgia. We believe our restructuring plan will reduce our cost base by consolidating our Utica, New York operations into a single facility and expanding our lower cost Mexican operations, as well as improve service to our customers by shipping orders from more centralized distribution centers. The transition of manufacturing operations and consolidation of distribution activities began in the third quarter of 2008 and is expected to be largely completed by the fourth quarter of 2009.

In conjunction with our restructuring plan, we considered Statement of Financial Accounting Standards No. 144 "Accounting for the Impairment or Disposal of Long-Lived Assets" ("SFAS 144"). SFAS 144 requires that long-lived assets be tested for recoverability whenever events or changes in circumstances indicate that their carrying amount may not be recoverable. Based on the announced restructuring plan, our current expectation is that it is more likely than not, that the two manufacturing facilities located in the Utica, New York area scheduled to be closed as a result of the restructuring plan, will be sold prior to the end of their previously estimated useful lives. Even though we expect to sell these facilities prior to the end of their useful lives, we do not believe that at present we meet the criteria contained within SFAS 144 to designate these assets as held for sale and accordingly we have tested them for impairment under the guidance for long-lived assets to be held and used. We performed our impairment testing on the two manufacturing facilities scheduled to close under the restructuring plan by comparing future cash flows expected to be generated by these facilities (undiscounted and without interest charges) against their carrying amounts (\$2.2 million and \$1.7 million, respectively, as of March 31, 2009). Since future cash flows expected to be generated by these facilities exceeds their carrying amounts, we do not believe any impairment exists at this time. However, we cannot be certain an impairment charge will not be taken in the future when the facilities are no longer in use.

As of March 31, 2009, we have incurred \$7.5 million (including \$3.5 million in the first quarter of 2009) in costs associated with the restructuring. Approximately \$5.4 million (including \$2.9 million in the first quarter of 2009) of the total \$7.5 million in restructuring costs have been charged to cost of goods sold. The \$5.4 million charged to cost of goods sold includes \$2.9 million in under utilization of production facilities (including \$1.7 million in the first quarter of 2009), \$0.7 million in accelerated depreciation (including \$0.3 million in the first quarter of 2009), \$0.4 million in severance related charges (including \$0.3 million in the first quarter of 2009), and \$1.4 million in other charges (including \$0.6 million in the first quarter of 2009).

The remaining \$2.1 million (including \$0.5 million in the first quarter of 2009) in restructuring costs have been recorded in other expense (income) and include charges related to the consolidation of our distribution centers. As our restructuring plan progresses, we will incur additional charges, including employee termination and other exit costs. Based on the criteria contained within Statement of Financial Accounting Standards No. 146 "Accounting for Costs Associated with Exit or Disposal Activities", we have accrued \$0.2 million in employee termination costs associated with the restructuring as of March 31, 2009.

Table of Contents

We estimate the total costs of the restructuring plan will approximate \$9.4 million during 2009, including \$2.1 million related to employee termination costs, \$3.7 million in expense related to abnormally low production levels at certain of our plants (as we transfer production to alternate sites), \$1.4 million in accelerated depreciation at one of the two Utica, New York area facilities which are expected to close and \$2.2 million in other restructuring related activities. We estimate approximately \$2.0 million of the total anticipated \$9.4 million in restructuring costs will be reported in other expense (income) with the remaining \$7.4 million charged to cost of goods sold. The restructuring plan impacts Corporate manufacturing and distribution facilities which support multiple reporting segments. As a result, costs associated with the restructuring plan will be reflected in the Corporate line within our business segment reporting.

Note 15 – Convertible senior subordinated notes

In May 2008, the FASB issued FASB Staff Position No. APB 14-1 (“FSP APB 14-1”). FSP APB 14-1 specifies that issuers of convertible debt instruments that permit or require the issuer to pay cash upon conversion should separately account for the liability and equity components in a manner that will reflect the entity’s nonconvertible debt borrowing rate when interest cost is recognized in subsequent periods. The Company is required to apply the guidance retrospectively to all past periods presented. We adopted this guidance on January 1, 2009.

We have outstanding \$115.1 million in 2.50% convertible senior subordinated notes due 2024 (“the Notes”). The Notes represent subordinated unsecured obligations and are convertible under certain circumstances, as defined in the bond indenture, into a combination of cash and CONMED common stock. Upon conversion, the holder of each Note will receive the conversion value of the Note payable in cash up to the principal amount of the Note and CONMED common stock for the Note’s conversion value in excess of such principal amount. Amounts in excess of the principal amount are at an initial conversion rate, subject to adjustment, of 26.1849 shares per \$1,000 principal amount of the Note (which represents an initial conversion price of \$38.19 per share). As of March 31, 2009, there was no value assigned to the conversion feature because the Company’s share price was below the conversion price. The Notes mature on November 15, 2024 and are not redeemable by us prior to November 15, 2011. Holders of the Notes will be able to require that we repurchase some or all of the Notes on November 15, 2011, 2014 and 2019.

The Notes contain two embedded derivatives. The embedded derivatives are recorded at fair value in other long-term liabilities and changes in their value are recorded through the consolidated statements of operations. The embedded derivatives have a nominal value, and it is our belief that any change in their fair value would not have a material adverse effect on our business, financial condition, results of operations or cash flows.

Our effective borrowing rate for nonconvertible debt at the time of issuance of the Notes was estimated to be 6.67%, which resulted in \$34.6 million of the \$150.0 million aggregate principal amount of Notes issued, or \$21.8 million after taxes, being attributable to equity. For the three months ended March 31, 2008 and 2009, we have recorded interest expense related to the amortization of debt discount on the Notes of \$1.2 million and \$1.0 million, respectively, at the effective interest rate of 6.67%. The debt discount on the Notes is being amortized through November 2011. For the three months ended March 31, 2008 and 2009, we have also recorded interest expense on the Notes of \$0.9 million and \$0.7 million, respectively, at the contractual coupon rate of 2.50%.

Table of Contents

The following table illustrates the effects of adopting FSP APB 14-1 on each Consolidated Condensed Balance Sheet line item as of December 31, 2008:

	As Originally Reported	As Adjusted	Effect of Change
Long-term debt	\$ 196,190	\$ 182,739	\$ (13,451)
Deferred income taxes	83,498	88,468	4,970
Total liabilities	399,927	391,446	(8,481)
Paid-in capital	292,251	313,830	21,579
Retained earnings	327,471	314,373	(13,098)
Total shareholders' equity	531,734	540,215	8,481

The following table illustrates the effects of adopting FSP APB 14-1 on each Consolidated Condensed Statement of Income and Consolidated Condensed Statement of Cash Flows line item for the three months ended March 31, 2008:

	As Originally Reported	As Adjusted	Effect of Change
Consolidated condensed statement of income:			
Notes discount amortization	\$ -	\$ 1,202	\$ 1,202
Income before income taxes	17,866	16,664	(1,202)
Provision for income taxes	6,856	6,412	(444)
Net income	11,010	10,252	(758)
EPS:			
Basic	\$.38	.36	\$ (.02)
Diluted	.38	.35	(.03)
Consolidated condensed statement of cash flow:			
Net Income	11,010	10,252	(758)
Notes discount amortization	-	1,202	1,202

Deferred taxes	5,779	5,335	(444)
----------------	-------	-------	-------

Table of Contents

Amounts recognized in the consolidated condensed balance sheets consist of the following:

	December 31, 2008	March 31, 2009
Principal value of the Notes	\$ 125,000	\$ 115,093
Unamortized discount	(13,451)	(11,390)
Carrying value of the Notes	\$ 111,549	\$ 103,703
Equity component	\$ 21,579	\$ 21,491

During the three months ended March 31, 2009, we repurchased and retired \$9.9 million of the Notes for \$7.8 million and recorded a gain on the early extinguishment of debt of \$1.1 million net of the write-off of \$0.1 million in unamortized deferred financing costs and write-off of \$1.0 million in unamortized debt discount.

Table of Contents

Item 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL
CONDITION
AND RESULTS OF OPERATIONS

Forward-looking statements

In this Report on Form 10-Q, we make forward-looking statements about our financial condition, results of operations and business. Forward-looking statements are statements made by us concerning events that may or may not occur in the future. These statements may be made directly in this document or may be "incorporated by reference" from other documents. Such statements may be identified by the use of words such as "anticipates", "expects", "estimates", "intends" and "believes" and variations thereof and other terms of similar meaning.

Forward-looking statements are not guarantees of future performance

Forward-looking statements involve known and unknown risks, uncertainties and other factors, including those that may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include those identified under "Risk Factors" in our Annual Report on Form 10-K for the year-ended December 31, 2008 and the following, among others:

- general economic and business conditions;
- changes in foreign exchange and interest rates;
- cyclical customer purchasing patterns due to budgetary and other constraints;
 - changes in customer preferences;
 - competition;
 - changes in technology;
- the introduction and acceptance of new products;
- the ability to evaluate, finance and integrate acquired businesses, products and companies;
 - changes in business strategy;
 - the availability and cost of materials;
- the possibility that United States or foreign regulatory and/or administrative agencies may initiate enforcement actions against us or our distributors;
 - future levels of indebtedness and capital spending;
- quality of our management and business abilities and the judgment of our personnel;
 - the availability, terms and deployment of capital;

- the risk of litigation, especially patent litigation as well as the cost associated with patent and other litigation; and
- changes in regulatory requirements.

See “Management’s Discussion and Analysis of Financial Condition and Results of Operations” below and “Risk Factors” and “Business” in our Annual Report on Form 10-K for the year-ended December 31, 2008 for a further discussion of these factors. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. We do not undertake any obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date of this Quarterly Report on Form 10-Q or to reflect the occurrence of unanticipated events.

Table of Contents

Overview:

CONMED Corporation (“CONMED”, the “Company”, “we” or “us”) is a medical technology company with six principal product lines. These product lines and the percentage of consolidated revenues associated with each, are as follows:

	Three months ended March 31,	
	2008	2009
Arthroscopy	39.7%	38.9%
Powered Surgical Instruments	21.1	20.0
Electrosurgery	14.0	13.6
Patient Care	10.6	11.3
Endosurgery	8.0	8.9
Endoscopic Technologies	6.6	7.3
Consolidated Net Sales	100%	100%

A significant amount of our products are used in surgical procedures with the majority of our revenues derived from the sale of disposable products. We manufacture substantially all of our products in facilities located in the United States, Mexico, and Finland. We market our products both domestically and internationally directly to customers and through distributors. International sales represent a significant portion of our business. During the three months ended March 31, 2009, sales to purchasers outside of the United States accounted for 44.4% of total net sales.

Business Environment and Opportunities

The aging of the worldwide population along with lifestyle changes, continued cost containment pressures on healthcare systems and the desire of clinicians and administrators to use less invasive (or noninvasive) procedures are important trends in our industry. We believe that with our broad product offering of high quality surgical and patient care products, we can capitalize on these trends for the benefit of the Company and our shareholders.

In order to further our growth prospects, we have historically used strategic business acquisitions and exclusive distribution relationships to continue to diversify our product offerings, increase our market share and realize economies of scale.

We have a variety of research and development initiatives focused in each of our principal product lines. Among the most significant of these efforts is the Endotracheal Cardiac Output Monitor (“ECOM”). Our ECOM product offering is expected to provide an innovative alternative to catheter monitoring of cardiac output with a specially designed endotracheal tube which utilizes proprietary bio-impedance technology. Also of significance are our research and development efforts in the area of tissue-sealing for electrosurgery.

Continued innovation and commercialization of new proprietary products and processes are essential elements of our long-term growth strategy. In February 2009, we unveiled several new products at the American Academy of Orthopaedic Surgeons Annual Meeting which we believe will further enhance our arthroscopy and powered surgical instrument product offerings. Our reputation as an innovator is exemplified by these product introductions, which include the following: the Zen™ Wireless Footswitch and Adaptor, incorporating the power of Zigbee® communications technology to provide three pedal control of CONMED Linvatec control consoles and hand pieces; the Paladin™ suture anchor, the latest addition to our arsenal for rotator cuff repair; the ReAct™ Arthroscopic Shaver Blades which have the ability to reciprocate while rotating; MPower® 2, the latest in our next generation of battery

power systems for large bone and small bone orthopedic surgery; and the VP1600 Digital Documentation System, a 1080p digital still capture unit which enables users to save and print the highest quality medical images.

Table of Contents

Business Challenges

Given significant volatility in the financial markets and foreign currency exchange rates and depressed economic conditions in both domestic and international markets, we believe 2009 will continue to present significant business challenges. We expect 2009 total revenues to decrease 7% to 8% from 2008 levels, reflecting lower sales volumes, especially of our capital products, and a significant unfavorable impact from foreign currency translation due to strengthening of the United States dollar as compared with currencies such as the Euro. We will continue to monitor and manage the impact of the deteriorating economic environment on the Company.

We are in the process of executing our operational restructuring plan which began in the third quarter of 2008. The restructuring plan includes the closure of two manufacturing facilities located in the Utica, New York area with manufacturing to be transferred into either our Corporate headquarters location in Utica, New York or into a newly constructed leased manufacturing facility in Chihuahua, Mexico. In addition, manufacturing presently done by a contract manufacturing facility in Juarez, Mexico is being transferred in-house to the Chihuahua facility. Finally, certain domestic distribution activities are being centralized in a new leased consolidated distribution center in Atlanta, Georgia. We believe the successful execution of our restructuring plan will lower our costs by consolidating our Utica, New York operations into a single facility and expanding our lower cost Mexican operations, as well as improve service to our customers by shipping orders from more centralized distribution centers. We expect the transition of manufacturing operations and consolidation of distribution activities to be largely completed by the fourth quarter of 2009. However, we cannot be certain such activities will be completed in the estimated time period or that planned cost savings will be achieved.

Our Endoscopic Technologies operating segment has suffered from sales declines and operating losses since its acquisition from C.R. Bard in September 2004. We have corrected the operational issues associated with product shortages that resulted following the acquisition of the Endoscopic Technologies business and continue to reduce costs while also investing in new product development in an effort to increase sales and achieve a return to profitability.

Our facilities are subject to periodic inspection by the United States Food and Drug Administration (“FDA”) for, among other things, conformance to Quality System Regulation and Current Good Manufacturing Practice (“CGMP”) requirements. We are committed to the principles and strategies of systems-based quality management for improved CGMP compliance, operational performance and efficiencies through our Company-wide quality systems initiative. However, there can be no assurance that our actions will ensure that we will not receive a warning letter or other regulatory action which may include consent decrees or fines.

Table of Contents

Critical Accounting Policies

Preparation of our financial statements requires us to make estimates and assumptions which affect the reported amounts of assets, liabilities, revenues and expenses. Note 1 to the consolidated financial statements in our Annual Report on Form 10-K for the year-ended December 31, 2008 describes significant accounting policies used in preparation of the consolidated financial statements. The most significant areas involving management judgments and estimates are described below and are considered by management to be critical to understanding the financial condition and results of operations of CONMED Corporation. There have been no significant changes in our critical accounting estimates during the quarter ended March 31, 2009.

Revenue Recognition

Revenue is recognized when title has been transferred to the customer which is at the time of shipment. The following policies apply to our major categories of revenue transactions:

- Sales to customers are evidenced by firm purchase orders. Title and the risks and rewards of ownership are transferred to the customer when product is shipped under our stated shipping terms. Payment by the customer is due under fixed payment terms.
- We place certain of our capital equipment with customers in return for commitments to purchase disposable products over time periods generally ranging from one to three years. In these circumstances, no revenue is recognized upon capital equipment shipment and we recognize revenue upon the disposable product shipment. The cost of the equipment is amortized over the term of individual commitment agreements.
- Product returns are only accepted at the discretion of the Company and in accordance with our “Returned Goods Policy”. Historically the level of product returns has not been significant. We accrue for sales returns, rebates and allowances based upon an analysis of historical customer returns and credits, rebates, discounts and current market conditions.
- Our terms of sale to customers generally do not include any obligations to perform future services. Limited warranties are provided for capital equipment sales and provisions for warranty are provided at the time of product sale based upon an analysis of historical data.
- Amounts billed to customers related to shipping and handling have been included in net sales. Shipping and handling costs are included in selling and administrative expense.
- We sell to a diversified base of customers around the world and, therefore, believe there is no material concentration of credit risk.
- We assess the risk of loss on accounts receivable and adjust the allowance for doubtful accounts based on this risk assessment. Historically, losses on accounts receivable have not been material. Management believes that the allowance for doubtful accounts of \$1.3 million at March 31, 2009 is adequate to provide for probable losses resulting from accounts receivable.

Table of Contents

Inventory Reserves

We maintain reserves for excess and obsolete inventory resulting from the inability to sell our products at prices in excess of current carrying costs. The markets in which we operate are highly competitive, with new products and surgical procedures introduced on an on-going basis. Such marketplace changes may result in our products becoming obsolete. We make estimates regarding the future recoverability of the costs of our products and record a provision for excess and obsolete inventories based on historical experience, expiration of sterilization dates and expected future trends. If actual product life cycles, product demand or acceptance of new product introductions are less favorable than projected by management, additional inventory write-downs may be required. We believe that our current inventory reserves are adequate.

Goodwill and Intangible Assets

We have a history of growth through acquisitions. Assets and liabilities of acquired businesses are recorded at their estimated fair values as of the date of acquisition. Goodwill represents costs in excess of fair values assigned to the underlying net assets of acquired businesses. Other intangible assets primarily represent allocations of purchase price to identifiable intangible assets of acquired businesses. We have accumulated goodwill of \$290.5 million and other intangible assets of \$194.6 million as of March 31, 2009.

In accordance with Statement of Financial Accounting Standards No. 142, "Goodwill and Other Intangible Assets" ("SFAS 142"), goodwill and intangible assets deemed to have indefinite lives are not amortized, but are subject to at least annual impairment testing. It is our policy to perform our annual impairment testing in the fourth quarter. The identification and measurement of goodwill impairment involves the estimation of the fair value of our reporting units. Estimates of fair value are based on the best information available as of the date of the assessment, which primarily incorporate management assumptions about expected future cash flows and other valuation techniques. Future cash flows may be affected by changes in industry or market conditions or the rate and extent to which anticipated synergies or cost savings are realized with newly acquired entities. We last completed our goodwill impairment testing as of October 1, 2008 and determined that no impairment existed at that date. Our CONMED Patient Care operating segment has the least excess of fair value over invested capital of our reporting units, although a 10% decrease in the estimated fair value of any of our reporting units at the date of our 2008 assessment would not have resulted in a goodwill impairment charge. We continue to monitor events and circumstances for triggering events which would more likely than not reduce the fair value of any of our reporting units and require us to perform impairment testing before the fourth quarter 2009.

Intangible assets with a finite life are amortized over the estimated useful life of the asset. SFAS 142 requires that intangible assets which continue to be subject to amortization be evaluated each reporting period to determine whether events and circumstances warrant a revision to the remaining period of amortization. SFAS 142 also requires that intangible assets subject to amortization be reviewed for impairment in accordance with Statement of Financial Accounting Standards No. 144, "Accounting for the Impairment or Disposal of Long-Lived Assets," ("SFAS 144"). SFAS 144 requires that intangible assets subject to amortization be tested for recoverability whenever events or changes in circumstances indicate that its carrying amount may not be recoverable. The carrying amount of an intangible asset subject to amortization is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use of the asset. An impairment loss is recognized by reducing the carrying amount of the intangible asset to its current fair value.

Table of Contents

Customer relationship assets arose principally as a result of the 1997 acquisition of Linvatec Corporation. These assets represent the acquisition date fair value of existing customer relationships based on the after-tax income expected to be derived during their estimated remaining useful life. The useful lives of these customer relationships were not and are not limited by contract or any economic, regulatory or other known factors. The estimated useful life of the Linvatec customer relationship assets was determined as of the date of acquisition as a result of a study of the observed pattern of historical revenue attrition during the 5 years immediately preceding the acquisition of Linvatec Corporation. This observed attrition pattern was then applied to the existing customer relationships to derive the future expected retirement of the customer relationships. This analysis indicated an annual attrition rate of 2.6%. Assuming an exponential attrition pattern, this equated to an average remaining useful life of approximately 38 years for the Linvatec customer relationship assets. Customer relationship intangible assets arising as a result of other business acquisitions are being amortized over a weighted average life of 17 years. The weighted average life for customer relationship assets in aggregate is 32 years.

In accordance with SFAS 142, we evaluate the remaining useful life of our customer relationship intangible assets each reporting period in order to determine whether events and circumstances warrant a revision to the remaining period of amortization. In order to further evaluate the remaining useful life of our customer relationship intangible assets, we perform an annual analysis and assessment of actual customer attrition and activity. This assessment includes a comparison of customer activity since the acquisition date and review of customer attrition rates. In the event that our analysis of actual customer attrition rates indicates a level of attrition that is in excess of that which was originally contemplated, we would change the estimated useful life of the related customer relationship asset with the remaining carrying amount amortized prospectively over the revised remaining useful life.

SFAS 144 requires that we test our customer relationship assets for recoverability whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. Factors specific to our customer relationship assets which might lead to an impairment charge include a significant increase in the annual customer attrition rate or otherwise significant loss of customers, significant decreases in sales or current-period operating or cash flow losses or a projection or forecast of losses. We do not believe that there have been events or changes in circumstances which would indicate the carrying amount of our customer relationship assets might not be recoverable.

Pension Plan

We sponsor a defined benefit pension plan (“the plan”) covering substantially all our United States-based employees. Major assumptions used in accounting for the plan include the discount rate, expected return on plan assets, rate of increase in employee compensation levels and expected mortality. Assumptions are determined based on Company data and appropriate market indicators, and are evaluated annually as of the plan’s measurement date. A change in any of these assumptions would have an effect on net periodic pension costs reported in the consolidated financial statements.

During the first quarter of 2009, we elected to freeze benefit accruals under the plan effective May 14, 2009. As a result, we recorded a curtailment gain of \$4.4 million and a reduction in accrued pension of \$11.4 million which is included in other long term liabilities. See Note 9 to the Consolidated Condensed Financial Statements.

Table of Contents

The weighted-average discount rate used to measure pension liabilities and costs is set by reference to the Citigroup Pension Liability Index. However, this index gives only an indication of the appropriate discount rate because the cash flows of the bonds comprising the index do not match the projected benefit payment stream of the plan precisely. For this reason, we also consider the individual characteristics of the plan, such as projected cash flow patterns and payment durations, when setting the discount rate. This discount rate, which is used in determining pension expense, increased from 5.90% in 2008 to 6.48% in the first quarter of 2009. The discount rate used for purposes of remeasuring plan liabilities and costs as of the date of the plan freeze was 7.30%.

We have used an expected rate of return on pension plan assets of 8.0% for purposes of determining the net periodic pension benefit cost. In determining the expected return on pension plan assets, we consider the relative weighting of plan assets, the historical performance of total plan assets and individual asset classes and economic and other indicators of future performance. In addition, we consult with financial and investment management professionals in developing appropriate targeted rates of return.

We have estimated our rate of increase in employee compensation levels at 3.5% consistent with our internal budgeting.

For the three months ending March 31, 2009 we recorded a net pension gain of \$1.9 million (including a \$4.4 million curtailment gain and pension expense of \$2.5 million). Pension expense for the full year 2009 is estimated at a gain of \$0.9 million (including a \$4.4 million curtailment gain and pension expense of \$3.5 million) compared to a \$6.9 million charge in 2008. The reduction in estimated pension expense in 2009 as compared with 2008 is due to the freeze in benefit accruals.

We have recorded additional expense of approximately \$1.0 million in the first quarter of 2009 related to an additional employer 401(k) contribution which is intended to offset some of the impact on employees of the freeze in pension benefit accruals. We expect the full year 2009 cost of the additional employer 401(k) contribution to approximate \$4.0 million.

Stock Based Compensation

In accordance with Statement of Financial Accounting Standards No. 123 (revised 2004), "Share-Based Payment" ("SFAS 123R") all share-based payments to employees, including grants of employee stock options, restricted stock units, and stock appreciation rights are recognized in the financial statements based at their fair values. Compensation expense is recognized using a straight-line method over the vesting period.

Income Taxes

The recorded future tax benefit arising from net deductible temporary differences and tax carryforwards is approximately \$32.3 million at March 31, 2009. Management believes that earnings during the periods when the temporary differences become deductible will be sufficient to realize the related future income tax benefits.

We operate in multiple taxing jurisdictions, both within and outside the United States. We face audits from these various tax authorities regarding the amount of taxes due. Such audits can involve complex issues and may require an extended period of time to resolve. The Internal Revenue Service ("IRS") has completed examinations of our United States federal income tax returns through 2007. Tax years subsequent to 2007 are subject to future examination.

Table of Contents

We have established a valuation allowance to reflect the uncertainty of realizing the benefits of certain net operating loss carryforwards recognized in connection with an acquisition. Effective January 1, 2009, the Company adopted of Statement of Financial Accounting Standards No. 141 (revised 2007), "Business Combinations" ("SFAS 141R"), whereby changes in deferred tax valuation allowances and income tax uncertainties after the acquisition date, including those associated with acquisitions that closed prior to the effective date of SFAS 141R, generally will affect income tax expense. In assessing the need for a valuation allowance, we estimate future taxable income, considering the feasibility of ongoing tax planning strategies and the realizability of tax loss carryforwards. Valuation allowances related to deferred tax assets may be impacted by changes to tax laws, changes to statutory tax rates and future taxable income levels.

Results of operations

Three months ended March 31, 2009 compared to three months ended March 31, 2008

The following table presents, as a percentage of net sales, certain categories included in our consolidated statements of income for the periods indicated:

	Three Months Ended March 31,	
	2008	2009
Net sales	100.0%	100.0%
Cost of sales	48.8	53.5
Gross profit	51.2	46.5
Selling and administrative expense	36.0	37.7
Research and development expense	4.2	5.2
Other expense (income)	-	(0.8)
Income from operations	11.0	4.4
Gain on early extinguishment of debt	-	0.7
Amortization of debt discount	0.6	0.6
Interest expense	1.6	0.9
Income before income taxes	8.8	3.6
Provision for income taxes	3.4	0.9
Net income	5.4%	2.7%

Sales for the quarterly period ended March 31, 2009 were \$164.1 million, a decrease of \$26.7 million (-14.0%) compared to sales of \$190.8 million in the comparable 2008 period with decreases across all product lines. Unfavorable foreign currency exchange rates (when compared to the foreign currency exchange rates in the same period a year ago) accounted for approximately \$13.0 million of the decrease. In local currency, sales decreased 7.2%. Sales of capital equipment decreased \$15.1 million (-28.5%) from \$52.9 million in the first quarter of 2008 to \$37.8 million in the first quarter of 2009; sales of disposable products decreased \$11.6 million (-8.4%) from \$137.9 million in the first quarter of 2008 to \$126.3 million in the first quarter of 2009. On a local currency basis, sales of capital equipment decreased 21.7% while disposable products decreased 1.6%.

Cost of sales decreased to \$87.7 million in the quarterly period ended March 31, 2009 as compared to \$93.0 million in the same period a year ago on overall decreases in sales volumes as described above. Gross profit margins decreased 4.7 percentage points to 46.5% in the quarterly period ended March 31, 2009 as compared to 51.2% in the same

period a year ago. The decrease in gross profit margins of 4.7 percentage points is primarily a result of the effects of unfavorable foreign currency exchange rates on sales (3.9 percentage points) and restructuring of the Company's operations as more fully described in Note 14 (2.2 percentage points) offset by improved product mix (1.4 percentage points).

Table of Contents

Selling and administrative expense decreased to \$61.9 million in the quarterly period ended March 31, 2009 as compared to \$68.6 million in the same period a year ago. Selling and administrative expense as a percentage of net sales increased to 37.7% in the quarterly period ended March 31, 2009 as compared to 36.0% in the same period a year ago as a result of lower sales. This increase of 1.7 percentage points is primarily attributable to higher sales force (1.4 percentage points) and other administrative expenses (0.3 percentage points).

Research and development expense totaled \$8.5 million in the quarterly period ended March 31, 2009 as compared to \$8.1 million in the same period a year ago. As a percentage of net sales, research and development expense increased 1.0 percentage points to 5.2% in the quarterly period ended March 31, 2009 as compared to 4.2% in the same period a year ago. The increase in research and development expense of 1.0 percentage point is mainly driven by increased spending on our CONMED Linvatec orthopedic products (0.8 percentage points) coupled with increases in other research and development spending (0.2 percentage points).

As discussed in Note 10 to the Consolidated Condensed Financial Statements, other expense (income) in the quarterly period ended March 31, 2009 consisted of a \$0.5 million charge related to the restructuring of certain of the Company's operations and \$1.9 million in income related to the net pension gain resulting from the freezing of future benefit accruals effective May 14, 2009.

During the first quarter of 2009, we repurchased and retired \$9.9 million of our 2.50% convertible senior subordinated notes (the "Notes") for \$7.8 million and recorded a gain on the early extinguishment of debt of \$1.1 million net of the write-off of \$0.1 million in unamortized deferred financing costs and write-off of the \$1.0 million in unamortized Notes discount. See additional discussion under Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations—Liquidity and Capital Resources and Note 15 to the Consolidated Condensed Financial Statements.

Amortization of debt discount in the quarterly period ended March 31, 2009 was \$1.0 million compared to \$1.2 million in the same period a year ago. This amortization is associated with the implementation of FASB Staff Position No. APB 14-1 ("FSP APB 14-1") as of January 1, 2009 as further described in Note 15 to the Consolidated Condensed Financial Statements.

Interest expense in the quarterly period ended March 31, 2009 was \$1.5 million as compared to \$3.2 million in the same period a year ago. The decrease in interest expense is due to lower weighted average borrowings outstanding in the quarterly period ended March 31, 2009 as compared to the same period a year ago. The weighted average interest rates on our borrowings (inclusive of the finance charge on our accounts receivable sale facility) also declined to 2.41% in the quarterly period ended March 31, 2009 as compared to 4.44% in the same period a year ago.

A provision for income taxes has been recorded at an effective tax rate of 23.9% for the quarterly period ended March 31, 2009 compared to the 38.5% effective tax rate recorded in the same period a year ago. The effective tax rate for the quarterly period ended March 31, 2009 is lower than that recorded in the same period a year ago as a result of settlement of our 2007 IRS examination, and the resulting adjustment to our reserves of \$1.1 million, reducing income tax expense. A reconciliation of the United States statutory income tax rate to our effective tax rate is included in our Annual Report on Form 10-K for the year-ended December 31, 2008, Note 6 to the Consolidated Financial Statements.

Table of Contents

Operating Segment Results:

Segment information is prepared on the same basis that we review financial information for operational decision-making purposes. We conduct our business through five principal operating segments: CONMED Endoscopic Technologies, CONMED Endosurgery, CONMED Electrosurgery, CONMED Linvatec and CONMED Patient Care. Based upon the aggregation criteria for segment reporting under Statement of Financial Accounting Standards No. 131 “Disclosures about Segments of an Enterprise and Related Information” (“SFAS 131”), we have grouped our CONMED Endosurgery, CONMED Electrosurgery and CONMED Linvatec operating units into a single segment. The economic characteristics of CONMED Patient Care and CONMED Endoscopic Technologies do not meet the criteria for aggregation due to the lower overall operating income (loss) of these segments.

The following tables summarize the Company’s results of operations by segment for the quarterly period ended March 31, 2008 and 2009:

CONMED Endosurgery, CONMED Electrosurgery and CONMED Linvatec

	2008	2009
Net sales	\$ 157,965	\$ 133,561
Income from operations	27,497	12,511
Operating margin	17.4%	9.4%

Product offerings include a complete line of endo-mechanical instrumentation for minimally invasive laparoscopic procedures, electrosurgical generators and related surgical instruments, arthroscopic instrumentation for use in orthopedic surgery and small bone, large bone and specialty powered surgical instruments.

- Arthroscopy sales decreased \$11.9 million (-15.7%) in the quarterly period ended March 31, 2009 to \$63.9 million from \$75.8 million in the comparable 2008 period as a result of decreased sales of our procedure specific, resection and video imaging products for arthroscopy and general surgery, and our integrated operating room systems and equipment. Unfavorable foreign currency exchange rates (when compared to the foreign currency exchange rates in the same period a year ago) accounted for approximately \$6.1 million of the decrease. Sales of capital equipment decreased \$7.5 million (-29.8%) from \$25.2 million in the first quarter of 2008 to \$17.7 million in the first quarter of 2009; sales of disposable products decreased \$4.4 million (-8.7%) from \$50.6 million in the first quarter of 2008 to \$46.2 million in the first quarter of 2009. On a local currency basis, sales of capital equipment decreased 23.9% while disposable products increased 0.2%.
- Powered surgical instrument sales decreased \$7.4 million (-18.4%) in the quarterly period ended March 31, 2009 to \$32.8 million from \$40.2 million in the comparable 2008 period, as a result of decreased sales of our small bone and large bone powered instrument handpieces. Unfavorable foreign currency exchange rates (when compared to the foreign currency exchange rates in the same period a year ago) accounted for approximately \$3.9 million of the decrease. Sales of capital equipment decreased \$5.0 million (-25.4%) from \$19.7 million in the first quarter of 2008 to \$14.7 million in the first quarter of 2009; sales of disposable products decreased \$2.4 million (-11.7%) from \$20.5 million in the first quarter of 2008 to \$18.1 million in the first quarter of 2009. On a local currency basis, sales of capital equipment decreased 17.2% while disposable products decreased 0.2%.

Table of Contents

- Electrosurgery sales decreased \$4.3 million (-16.1%) in the quarterly period ended March 31, 2009 to \$22.4 million from \$26.7 million in the comparable 2008 period, as a result of decreased sales of electrosurgical generators, ABC® handpieces, electrodes and pencils. Unfavorable foreign currency exchange rates (when compared to the foreign currency exchange rates in the same period a year ago) accounted for approximately \$1.0 million of the decrease. Sales of capital equipment decreased \$2.6 million (-32.5%) from \$8.0 million in the first quarter of 2008 to \$5.4 million in the first quarter of 2009; sales of disposable products decreased \$1.7 million (-9.1%) from \$18.7 million in the first quarter of 2008 to \$17.0 million in the first quarter of 2009. On a local currency basis, sales of capital equipment decreased 26.1% while disposable products decreased 6.6%.
- Endosurgery sales decreased \$0.7 million (-4.4%) in the quarterly period ended March 31, 2009 to \$14.5 million from \$15.2 million in the comparable 2008 period as a result of decreased sales of disposable handheld instruments, suction irrigation products and trocars. Unfavorable foreign currency exchange rates (when compared to the foreign currency exchange rates in the same period a year ago) accounted for approximately \$0.9 million of the decrease. On local currency basis, sales increased 1.5%.
- Operating margins as a percentage of net sales decreased 8.0 percentage points to 9.4% in 2009 compared to 17.4% in 2008 principally as a result of lower gross margins (3.6 percentage points) due to unfavorable foreign currency exchange rates and higher research and development spending (1.1 percentage points) due to increased emphasis on our CONMED Linvatec orthopedic products. In addition, we experienced higher sales force and other administrative expenses (3.3 percentage points) as a percent of sales as lower sales resulted in expenses being a higher percentage of sales.

CONMED Patient Care

	2008	2009
Net sales	\$ 20,311	\$ 18,465
Income (loss) from operations	554	(440)
Operating margin	2.7%	(2.4%)

Product offerings include a line of vital signs and cardiac monitoring products including pulse oximetry equipment & sensors, ECG electrodes and cables, cardiac defibrillation & pacing pads and blood pressure cuffs. We also offer a complete line of reusable surgical patient positioners and suction instruments & tubing for use in the operating room, as well as a line of IV products.

- Patient care sales decreased \$1.9 million (-9.3%) in the quarterly period ended March 31, 2009 to \$18.5 million from \$20.4 million in the comparable 2008 period as a result of decreased sales of disposable suction instruments and ECG electrodes. Unfavorable foreign currency exchange rates (when compared to the foreign currency exchange rates in the same period a year ago) accounted for approximately \$0.3 million of the decrease. On a local currency basis, sales decreased 7.7%.

Table of Contents

- Operating margins as a percentage of net sales decreased 5.1 percentage points to -2.4% in 2009 compared to 2.7% in 2008. The decrease in operating margins of 5.1 percentage points was driven by higher sales force related spending (2.0 percentage points), higher research and development spending (1.4 percentage points) and other administrative expenses (1.7 percentage points).

CONMED Endoscopic Technologies

	2008	2009
Net sales	\$ 12,497	\$ 12,036
Income (loss) from operations	(2,479)	(1,842)
Operating margin	(19.8%)	(15.3%)

Product offerings include a comprehensive line of minimally invasive endoscopic diagnostic and therapeutic instruments used in procedures which require examination of the digestive tract.

- Endoscopic Technologies sales of disposable products decreased \$0.5 million (-4.0%) in the quarterly period ended March 31, 2009 to \$12.0 million from \$12.5 million in the comparable 2008 period. Unfavorable foreign currency exchange rates (when compared to the foreign currency exchange rates in the same period a year ago) accounted for approximately \$0.8 million of the decrease. On a local currency basis, sales increased 2.4%.
- Operating margins as a percentage of net sales increased 4.5 percentage points to -15.3% in 2009 compared to -19.8% in 2008. This increase is principally a result of lower research and development spending (2.1 percentage points) and overall lower spending in selling and administrative expenses (2.4 percentage points).

Liquidity and capital resources

Our liquidity needs arise primarily from capital investments, working capital requirements and payments on indebtedness under our senior credit agreement. We have historically met these liquidity requirements with funds generated from operations, including sales of accounts receivable and borrowings under our revolving credit facility. In addition, we use term borrowings, including borrowings under our senior credit agreement and borrowings under separate loan facilities, in the case of real property purchases, to finance our acquisitions. We also have the ability to raise funds through the sale of stock or we may issue debt through a private placement or public offering.

Cash provided by operations

Our net working capital position was \$223.5 million at March 31, 2009. Net cash provided by operating activities was \$6.7 million in the quarterly period ended March 31, 2009 and \$20.8 million in the quarterly period ended March 31, 2008.

Table of Contents

Net cash provided by operating activities decreased by \$14.0 million in 2009 as compared to 2008 on a \$5.8 million decrease in net income in the current quarter as compared to the same period a year ago. In addition to the decrease in net income, the noncash nature of certain components of current period net income including a \$1.1 million non-cash gain on the repurchase and retirement of our 2.50% convertible senior subordinated notes, a \$1.9 million non-cash net pension gain and a net \$5.0 million decrease in the sale of accounts receivable from the same period a year ago all contributed to the reduction in net cash provided by operating activities.

Investing cash flows

Net cash used in investing activities in the quarterly period ended March 31, 2009 consisted primarily of capital expenditures. Capital expenditures were \$6.0 million and \$7.4 million for the quarterly periods ended March 31, 2008 and 2009, respectively. The increase in capital expenditures in the quarterly period ended March 31, 2009 as compared to the same period a year ago is primarily due to the ongoing implementation of an enterprise business software application as well various other infrastructure improvements related to our restructuring efforts as more fully described in Note 14 and in "Restructuring" below. The implementation of the enterprise business software application is scheduled to conclude in the second quarter of 2009 which should result in lower capital expenditures during the remainder of 2009. Capital expenditures are expected to approximate \$25.0 million in 2009.

Financing cash flows

Net cash provided by financing activities in the three months ended March 31, 2009 consist principally of \$12.0 million in borrowings on our revolving credit facility under our senior credit agreement, a \$3.2 million net change in cash overdrafts, and a \$7.8 million repurchase of our 2.50% convertible senior subordinated notes. See Note 15 to the Consolidated Condensed Financial Statements for further discussion of the repurchase of the Notes.

Our \$235.0 million senior credit agreement (the "senior credit agreement") consists of a \$100.0 million revolving credit facility and a \$135.0 million term loan. There were \$16.0 million in borrowings outstanding on the revolving credit facility as of March 31, 2009. Our available borrowings on the revolving credit facility at March 31, 2009 were \$77.0 million with approximately \$7.0 million of the facility set aside for outstanding letters of credit. There were \$57.3 million in borrowings outstanding on the term loan at March 31, 2009.

Borrowings outstanding on the revolving credit facility are due and payable on April 12, 2011. The scheduled principal payments on the term loan portion of the senior credit agreement are \$1.4 million annually through December 2011, increasing to \$53.6 million in 2012 with the remaining balance outstanding due and payable on April 12, 2013. We may also be required, under certain circumstances, to make additional principal payments based on excess cash flow as defined in the senior credit agreement. Interest rates on the term loan portion of the senior credit agreement are at LIBOR plus 1.50% (2.02% at March 31, 2009) or an alternative base rate; interest rates on the revolving credit facility portion of the senior credit agreement are at LIBOR plus 1.25% or an alternative base rate (3.50% at March 31, 2009). For those borrowings where the Company elects to use the alternative base rate, the base rate will be the greater of the Prime Rate or the Federal Funds Rate in effect on such date plus 0.50%, plus a margin of 0.50% for term loan borrowings or 0.25% for borrowings under the revolving credit facility.

Table of Contents

The senior credit agreement is collateralized by substantially all of our personal property and assets, except for our accounts receivable and related rights which are pledged in connection with our accounts receivable sales agreement. The senior credit agreement contains covenants and restrictions which, among other things, require the maintenance of certain financial ratios, and restrict dividend payments and the incurrence of certain indebtedness and other activities, including acquisitions and dispositions. We were in compliance with these covenants and restrictions as of March 31, 2009. We are also required, under certain circumstances, to make mandatory prepayments from net cash proceeds from any issue of equity and asset sales.

Mortgage notes outstanding in connection with the property and facilities utilized by our CONMED Linvatec subsidiary consist of a note bearing interest at 7.50% per annum with semiannual payments of principal and interest through June 2009 (the "Class A note"); and a note bearing interest at 8.25% per annum compounded semiannually through June 2009, after which semiannual payments of principal and interest will commence, continuing through June 2019 (the "Class C note"). The principal balances outstanding on the Class A note and Class C note aggregated \$1.4 million and \$11.5 million, respectively, at March 31, 2009. These mortgage notes are collateralized by the CONMED Linvatec property and facilities.

We have outstanding \$115.1 million in 2.50% convertible senior subordinated notes due 2024 ("the Notes"). During the three months ended March 31, 2009, we repurchased and retired \$9.9 million of the Notes for \$7.8 million and recorded a gain on the early extinguishment of debt of \$1.1 million net of the write-offs of \$0.1 million in unamortized deferred financing costs and \$1.0 million in unamortized debt discount. The Notes represent subordinated unsecured obligations and are convertible under certain circumstances, as defined in the bond indenture, into a combination of cash and CONMED common stock. Upon conversion, the holder of each Note will receive the conversion value of the Note payable in cash up to the principal amount of the Note and CONMED common stock for the Note's conversion value in excess of such principal amount. Amounts in excess of the principal amount are at an initial conversion rate, subject to adjustment, of 26.1849 shares per \$1,000 principal amount of the Note (which represents an initial conversion price of \$38.19 per share). As of March 31, 2009, there was no value assigned to the conversion feature because the Company's share price was below the conversion price. The Notes mature on November 15, 2024 and are not redeemable by us prior to November 15, 2011. Holders of the Notes will be able to require that we repurchase some or all of the Notes on November 15, 2011, 2014 and 2019.

The Notes contain two embedded derivatives. The embedded derivatives are recorded at fair value in other long-term liabilities and changes in their value are recorded through the consolidated statements of operations. The embedded derivatives have a nominal value, and it is our belief that any change in their fair value would not have a material adverse effect on our business, financial condition, results of operations or cash flows.

Our Board of Directors has authorized a share repurchase program under which we may repurchase up to \$50.0 million of our common stock in any calendar year. We did not repurchase any shares during the first quarter of 2009. We may finance additional repurchases through the proceeds from the issuance of common stock under our stock option plans, from operating cash flow and from available borrowings under our revolving credit facility.

Management believes that cash flow from operations, including accounts receivable sales, cash and cash equivalents on hand and available borrowing capacity under our senior credit agreement will be adequate to meet our anticipated operating working capital requirements, debt service, funding of capital expenditures and common stock repurchases, if any, in the foreseeable future.

Table of Contents

Off-balance sheet arrangements

We have an accounts receivable sales agreement pursuant to which we and certain of our subsidiaries sell on an ongoing basis certain accounts receivable to CONMED Receivables Corporation (“CRC”), a wholly-owned, bankruptcy-remote, special-purpose subsidiary of CONMED Corporation. CRC may in turn sell up to an aggregate \$50.0 million undivided percentage ownership interest in such receivables (the “asset interest”) to a bank (the “purchaser”). The purchaser’s share of collections on accounts receivable are calculated as defined in the accounts receivable sales agreement, as amended. Effectively, collections on the pool of receivables flow first to the purchaser and then to CRC, but to the extent that the purchaser’s share of collections may be less than the amount of the purchaser’s asset interest, there is no recourse to CONMED or CRC for such shortfall. For receivables which have been sold, CONMED Corporation and its subsidiaries retain collection and administrative responsibilities as agent for the purchaser. As of March 31, 2009, the undivided percentage ownership interest in receivables sold by CRC to the purchaser aggregated \$40.0 million, which has been accounted for as a sale and reflected in the balance sheet as a reduction in accounts receivable. Expenses associated with the sale of accounts receivable, including the purchaser’s financing costs to purchase the accounts receivable were \$0.2 million in the three month period ended March 31, 2009 and are included in interest expense.

There are certain statistical ratios, primarily related to sales dilution and losses on accounts receivable, which must be calculated and maintained on the pool of receivables in order to continue selling to the purchaser. The pool of receivables is in full compliance with these ratios. Management believes that additional accounts receivable arising in the normal course of business will be of sufficient quality and quantity to meet the requirements for sale under the accounts receivables sales agreement. In the event that new accounts receivable arising in the normal course of business do not qualify for sale, then collections on sold receivables will flow to the purchaser rather than being used to fund new receivable purchases. To the extent that such collections would not be available to CONMED in the form of new receivables purchases, we would need to access an alternate source of working capital, such as our \$100 million revolving credit facility. Our accounts receivable sales agreement, as amended, also requires us to obtain a commitment (the “purchaser commitment”) from the purchaser to fund the purchase of our accounts receivable. The purchaser commitment was amended effective December 28, 2007 whereby it was extended through October 31, 2009 under substantially the same terms and conditions.

Restructuring

During the second quarter of 2008, we announced a plan to restructure certain of our operations. The restructuring plan includes the closure of two manufacturing facilities located in the Utica, New York area totaling approximately 200,000 square feet with manufacturing to be transferred into either our Corporate headquarters location in Utica, New York or into a newly constructed leased manufacturing facility in Chihuahua, Mexico. In addition, manufacturing presently done by a contract manufacturing facility in Juarez, Mexico is being transferred in-house to the Chihuahua facility. Finally, certain domestic distribution activities are being centralized in a new leased consolidated distribution center in Atlanta, Georgia. We believe our restructuring plan will reduce our cost base by consolidating our Utica, New York operations into a single facility and expanding our lower cost Mexican operations, as well as improve service to our customers by shipping orders from more centralized distribution centers. The transition of manufacturing operations and consolidation of distribution activities began in the third quarter of 2008 and is expected to be largely completed by the fourth quarter of 2009.

Table of Contents

In conjunction with our restructuring plan, we considered Statement of Financial Accounting Standards No. 144 "Accounting for the Impairment or Disposal of Long-Lived Assets" ("SFAS 144"). SFAS 144 requires that long-lived assets be tested for recoverability whenever events or changes in circumstances indicate that their carrying amount may not be recoverable. Based on the announced restructuring plan, our current expectation is that it is more likely than not, that the two manufacturing facilities located in the Utica, New York area scheduled to be closed as a result of the restructuring plan, will be sold prior to the end of their previously estimated useful lives. Even though we expect to sell these facilities prior to the end of their useful lives, we do not believe that at present we meet the criteria contained within SFAS 144 to designate these assets as held for sale and accordingly we have tested them for impairment under the guidance for long-lived assets to be held and used. We performed our impairment testing on the two manufacturing facilities scheduled to close under the restructuring plan by comparing future cash flows expected to be generated by these facilities (undiscounted and without interest charges) against their carrying amounts (\$2.2 million and \$1.7 million, respectively, as of March 31, 2009). Since future cash flows expected to be generated by these facilities exceeds their carrying amounts, we do not believe any impairment exists at this time. However, we cannot be certain an impairment charge will not be taken in the future when the facilities are no longer in use.

As of March 31, 2009, we have incurred \$7.5 million (including \$3.5 million in the first quarter of 2009) in costs associated with the restructuring. Approximately \$5.4 million (including \$2.9 million in the first quarter of 2009) of the total \$7.5 million in restructuring costs have been charged to cost of goods sold. The \$5.4 million charged to cost of goods sold includes \$2.9 million in under utilization of production facilities (including \$1.7 million in the first quarter of 2009), \$0.7 million in accelerated depreciation (including \$0.3 million in the first quarter of 2009), \$0.4 million in severance related charges (including \$0.3 million in the first quarter of 2009), and \$1.4 million in other charges (including \$0.6 million in the first quarter of 2009).

The remaining \$2.1 million (including \$0.5 million in the first quarter of 2009) in restructuring costs have been recorded in other expense (income) and include charges related to the consolidation of our distribution centers. As our restructuring plan progresses, we will incur additional charges, including employee termination and other exit costs. Based on the criteria contained within Statement of Financial Accounting Standards No. 146 "Accounting for Costs Associated with Exit or Disposal Activities", we have accrued \$0.2 million in employee termination costs associated with the restructuring as of March 31, 2009.

We estimate the total costs of the restructuring plan will approximate \$9.4 million during 2009, including \$2.1 million related to employee termination costs, \$3.7 million in expense related to abnormally low production levels at certain of our plants (as we transfer production to alternate sites), \$1.4 million in accelerated depreciation at one of the two Utica, New York area facilities which are expected to close and \$2.2 million in other restructuring related activities. We estimate approximately \$2.0 million of the total anticipated \$9.4 million in restructuring costs will be reported in other expense (income) with the remaining \$7.4 million charged to cost of goods sold. The restructuring plan impacts Corporate manufacturing and distribution facilities which support multiple reporting segments. As a result, costs associated with the restructuring plan will be reflected in the Corporate line within our business segment reporting.

Table of Contents

New accounting pronouncements

See Note 13 to the Consolidated Condensed Financial Statements for a discussion of new accounting pronouncements.

Item 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

There have been no significant changes in our primary market risk exposures or in how these exposures are managed during the three month period ended March 31, 2009. Reference is made to Item 7A. of our Annual Report on Form 10-K for the year-ended December 31, 2008 for a description of Qualitative and Quantitative Disclosures About Market Risk.

Item 4. CONTROLS AND PROCEDURES

An evaluation of the effectiveness of the design and operation of the Company's disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended ("Exchange Act")) was carried out under the supervision and with the participation of the Company's management, including the President and Chief Executive Officer and the Vice President-Finance and Chief Financial Officer ("the Certifying Officers") as of March 31, 2009. Based on that evaluation, the Certifying Officers concluded that the Company's disclosure controls and procedures are effective. There have been no changes in the Company's internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the quarter ended March 31, 2009 that have materially affected, or are reasonably likely to materially affect, the Company's internal control over financial reporting.

PART II OTHER INFORMATION

Item 1. LEGAL PROCEEDINGS

Reference is made to Item 3 of the Company's Annual Report on Form 10-K for the year-ended December 31, 2008 and to Note 12 of the Notes to Consolidated Condensed Financial Statements included in Part I of this Report for a description of certain legal matters.

Table of Contents

Item 6. EXHIBITS

Exhibit No.	Description of Exhibit
31.1	Certification of Joseph J. Corasanti pursuant to Rule 13a-14(a) or Rule 15d-14(a), of the Securities Exchange Act, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2	Certification of Robert D. Shallish, Jr. pursuant to Rule 13a-14(a) or Rule 15d-14(a), of the Securities Exchange Act, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1	Certification of Joseph J. Corasanti and Robert D. Shallish, Jr. pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

CONMED CORPORATION
(Registrant)

Date: May 1, 2009

/s/ Robert D. Shallish, Jr.
Robert D. Shallish, Jr.
Vice President - Finance and Chief
Financial Officer
(Principal Financial Officer)

Table of Contents

Exhibit Index

Exhibit		Sequential Page Number
<u>31.1</u>	Certification of Joseph J. Corasanti pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002	E-1
<u>31.2</u>	Certification of Robert D. Shallish, Jr. pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002	E-2
<u>32.1</u>	Certification of Joseph J. Corasanti and Robert D. Shallish, Jr. pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002	E-3